Souhaitez-vous accéder aux communiqués récents ?

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the...

Det nye produkt til transanal irrigation er designet til at lette hverdagen for mennesker, der har afførings- eller lækageproblemer. Det estimeres, at 10-15% af verdens befolkning lider af...

The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world’s population are affected...

Q1 2023/24Delårsrapport, 1. kvartal 2023/241. oktober 2023 – 31. december 2023 Coloplast leverede et solidt 1. kvartal med 8% organisk vækst og en overskudsgrad1) på 28%. Den rapporterede...

Q1 2023/24Interim financial results, Q1 2023/241 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported...

Selskabet sigter efter at udvide sin position inden for avanceret sårbehandling ved at introducere en ny sårbandage, der gavner både sundhedspersonale og patienter. ”Vi introducerer nu dette nye...

The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. “We are now introducing new...

Friday, 9 February 2024 at 11.00 - 12.00 CETIn connection with the publication of Coloplast’s interim financial results for Q1 2023/24, to be released same day around 07.30 am CET, Coloplast will host...

I dag, den 7. december 2023, har Coloplast A/S afholdt ordinær generalforsamling, hvor EY Godkendt Revisionspartnerselskab blev valgt som Coloplast A/S’ revisor i overensstemmelse med forslaget fra...

Today, 7 December 2023, Coloplast A/S held its Annual General Meeting, at which EY Godkendt Revisionspartnerselskab was elected as Coloplast A/S’ auditors in line with the proposal from the Board of...